Results 1 to 10 of about 4,718 (116)

Impact of Induction Therapy in Low Immunological Risk Simultaneous Pancreas-Kidney Transplantation [PDF]

Transplant International
T-cell depleting agents and IL-2 receptor blockers are the most common induction therapies in simultaneous pancreas-kidney transplantation (SPKT), but the optimal choice remains debated.
Enrique Montagud-Marrahi, Enrique Montagud-Marrahi, Enrique Montagud-Marrahi, Adriana Rodriguez-Gonzalo, Joan Vidiella-Martin, Blanca Martin Álvarez, Irving Gaston Ramírez, Albert Baronet, Joana Ferrer-Fàbrega, Antonio J. Amor, Maria José Ramírez-Bajo, Mireia Musquera, Fritz Diekmann, Fritz Diekmann, Fritz Diekmann, Pedro Ventura-Aguiar, Pedro Ventura-Aguiar, Pedro Ventura-Aguiar   +17 more
doaj   +2 more sources

Safe Administration of Immunosuppression in Japanese Monkeys: Relevance to Preclinical Xenotransplantation Studies [PDF]

Cell Transplantation
The Japanese monkey has been used in several animal studies; however, its potential as a recipient model for xenotransplantation is unclear. The potential of the Japanese monkey as a recipient for xenotransplantation was assessed using two experimental ...
Naoaki Sakata, Gumpei Yoshimatsu, Ryo Kawakami, Shohta Kodama   +3 more
doaj   +2 more sources

Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial [PDF]

Journal of Nephropathology, 2020
Introduction: Thymoglobulin is a lymphocyte-depleting polyclonal antibody, administered for induction therapy at the time of kidney transplantation to reduce the risk of acute allograft rejection.
Heshmatollah Shahbazian, Ali Ghorbani, Fatemeh Hayati, Seyed Seifollah Beladi Mousavi, Leila Sabetnia, Shahla Ahmadi Halili, Shokouh Shayanpour, Isa Rezaee   +7 more
doaj   +1 more source

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study [PDF]

Kidney Research and Clinical Practice, 2023
Background Generally, an induction agent is chosen based on the conditions of the deceased donor and the recipient. Antithymocyte globulin (ATG) is preferred in relatively high-risk conditions.
Su Yeon Hong, Young Soo Kim, Kyubok Jin, Seungyeup Han, Chul Woo Yang, Byung Ha Chung, Woo Yeong Park   +6 more
doaj   +1 more source

Single dose thymoglobulin induction therapy in prevention of acute rejection in renal transplant recipients [PDF]

Journal of Nephropharmacology, 2018
Introduction: The goal of induction therapy in developing countries should be prevention of acute rejection with access to immunosuppressive therapy on a cost-effective basis for maintaining allograft function.
Georgi Abraham, Madhusudan Vijayan, Rajeevalochana Parthasarathy, Milly Mathew, Saravanan Sundararaj, Priyanka Koshy, Sam Nishanth, Kalpana Sakthivel   +7 more
doaj   +1 more source

Outcomes of thymoglobulin versus basiliximab induction therapies in living donor kidney transplant recipients with mild to moderate immunological risk – a retrospective analysis of UNOS database

Annals of Medicine, 2023
Introduction The aim of this study is to assess the outcomes of different induction therapies among mild to moderate immunological risk kidney transplants in the era tacrolimus and mycophenolate-derivate based maintenance.Methods This was a retrospective
Hatem Ali, Mahmoud Mohammed, Tibor Fülöp, Shafi Malik   +3 more
doaj   +1 more source

The Interferon-Gamma +874 A/T Polymorphism Is Not Associated With CMV Infection After Kidney Transplantation

Frontiers in Immunology, 2020
The +874 A/T polymorphism in the interferon gamma (IFNG) gene has been associated with Cytomegalovirus (CMV) infection risk in lung and kidney transplant recipients.
Jose Luis Santiago, Isabel Pérez-Flores, Luis Sánchez-Pérez, Maria Angeles Moreno de la Higuera, Natividad Calvo-Romero, Javier Querol-García, Esther Culebras, Elena Urcelay, Cristina Fernández-Pérez, Ana Isabel Sánchez-Fructuoso   +9 more
doaj   +1 more source

COVID-19: Infection or Autoimmunity

Frontiers in Immunology, 2020
The clinical and laboratory features of COVID-19 are reviewed with attention to the immunologic manifestations of the disease. Recent COVID-19 publications describe a variety of clinical presentations including an asymptomatic state, pneumonia, a ...
Timothy Icenogle
doaj   +1 more source

Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products

Frontiers in Immunology, 2021
Acute graft-versus-host disease (GVHD) is a life-threatening complication that can develop after allogeneic hematopoietic stem cell transplantation. In particular, the prognosis of patients with steroid-refractory acute GVHD is extremely poor.
Makoto Murata, Takanori Teshima
doaj   +1 more source

Proceeding of the European Group for Blood and Marrow Transplantation (EBMT) congress on sickle cell disease, 16–17 may 2019, Regensburg, Germany What is the impact of antithymocyte globulin pharmacokinetics on haploidentical hematopoietic stem cell transplantation?

Hematology/Oncology and Stem Cell Therapy, 2020
Antithymocyte globulin (ATG) is a widely accepted part of the conditioning regimen applied in the setting of hematopoietic stem cell transplantation (HSCT) to prevent graft rejection and graft-versus-host disease.
Lisa V.E. Oostenbrink, Cornelia M. Jol-van der Zijde, Anja M. Jansen-Hoogendijk, Emma S. Pool, Astrid G.S. van Halteren, Dirk Jan A.R. Moes, Robbert G.M. Bredius, Alex B. Mohseny, Frans J.W. Smiers, Maarten J.D. van Tol, Marco W. Schilham, Arjan C. Lankester   +11 more
doaj   +1 more source